Patient-Generated Health Data

Patient-Generated Health Data (PGHD) refers to health-related data created, recorded, or gathered by patients or their authorized caregivers outside of any clinical setting. Its emergence is driven by the proliferation of wearable devices and mobile health applications. Examples include blood glucose readings, activity levels, and symptom logs. Under regulations like the EU's GDPR, PGHD is classified as 'data concerning health' (Article 9), a special category requiring explicit consent and stringent protection. For enterprise risk management, PGHD must be managed within a framework compliant with standards like ISO/IEC 27701 (Privacy Information Management System). Unlike Electronic Health Records (EHRs) created by clinicians, PGHD provides a continuous, real-world view of a patient's health, demanding robust governance for data accuracy, security, and privacy.

In enterprise risk management, applying PGHD requires a structured approach to mitigate privacy and security risks. Key implementation steps include: 1) Establishing a Data Governance Framework: Based on standards like ISO/IEC 27701, organizations must define clear policies for PGHD classification, access control, and retention, supported by a Privacy Impact Assessment (PIA). 2) Implementing Robust Technical Controls: This involves deploying end-to-end encryption, utilizing pseudonymization techniques, and securing APIs. 3) Continuous Compliance Monitoring: Enterprises must regularly audit access logs, verify patient consent, and conduct incident response drills. For example, a Taiwanese digital therapeutics company reduced its potential liability for non-compliance by 40% after implementing these steps, as measured by a pre- and post-implementation risk assessment. This proactive management ensures regulatory adherence and builds stakeholder trust.

Taiwan enterprises face several key challenges. First, regulatory ambiguity in the local Personal Data Protection Act, compared to the specificity of GDPR, creates compliance uncertainty for secondary data use and international transfers. Second, a lack of data interoperability is a major technical hurdle; PGHD from various devices often lacks a standardized format like HL7 FHIR, hindering reliable data integration. Third, managing dynamic and granular user consent is operationally complex. To overcome these, enterprises should adopt GDPR as a high-water mark for their privacy programs, prioritizing 'Privacy by Design'. A priority action is to invest in a data-mapping project to prepare for adopting the HL7 FHIR standard within 6-9 months. Furthermore, deploying a dedicated consent management platform is crucial to automate and simplify handling user permissions transparently.

Winners Consulting specializes in Patient-Generated Health Data for Taiwan enterprises, delivering compliant management systems within 90 days. Free consultation: https://winners.com.tw/contact